Retatrutide vs Ozempic: 7 Major Trial Findings for 2026

Retatrutide vs Ozempic: 7 Major Trial Findings for 2026

A new Phase 3 trial has put retatrutide vs Ozempic into the spotlight. Eli Lilly announced on October 28, 2026, that its investigational once-weekly drug retatrutide produced greater average A1C reductions and substantially more weight loss than Ozempic 2 mg in adults with type 2 diabetes.

HealthFling visual guide illustrating Retatrutide vs Ozempic: 7 Major Trial Findings for 2026
HealthFling visual guide for Retatrutide vs Ozempic: 7 Major Trial Findings for 2026.

The headline numbers are striking, but they need context. Retatrutide is still investigational and is not approved by the U.S. Food and Drug Administration or any other regulatory agency. The results are topline findings from a company-sponsored trial, and detailed peer-reviewed results have not yet been published.

Here are seven important things to know about the retatrutide vs Ozempic comparison before drawing conclusions.

What Did the New Retatrutide vs Ozempic Trial Find?

The TRANSCEND-T2D-2 study was a Phase 3, randomized, open-label trial involving 1,298 adults with type 2 diabetes that was not adequately controlled with metformin, with or without an SGLT2 inhibitor.

Participants were assigned to retatrutide 9 mg, retatrutide 12 mg, or Ozempic 2 mg once weekly.

After 80 weeks, both retatrutide groups reduced A1C by an average of 2.2 percentage points, compared with 1.8 percentage points with Ozempic 2 mg.

Weight loss was also greater in the retatrutide groups. Participants receiving 9 mg lost an average of 19.5% of body weight, while those receiving 12 mg lost 20.9%. The Ozempic group lost an average of 9.4%.

The average starting weight was about 225.8 pounds. That translated to approximately 44.3 pounds lost with retatrutide 9 mg, 47.4 pounds with retatrutide 12 mg, and 20.9 pounds with Ozempic 2 mg.

1. Retatrutide Produced More Average Weight Loss in This Trial

The biggest reason the retatrutide vs Ozempic results are attracting attention is the difference in average weight loss.

Retatrutide 9 mg: 19.5% average body-weight reduction
Retatrutide 12 mg: 20.9% average body-weight reduction
Ozempic 2 mg: 9.4% average body-weight reduction

That means the highest retatrutide dose produced more than twice the average percentage weight loss seen with Ozempic 2 mg in this specific trial population.

However, this does not mean every person would lose around 20% of their body weight. It also does not prove retatrutide is universally better for every patient.

Individual results can vary, and this trial enrolled adults with type 2 diabetes rather than a general population of people trying to lose weight.

2. Blood-Sugar Control Was Also Stronger With Retatrutide

Weight loss was not the only endpoint.

The study’s primary objective focused on A1C, a measure used to evaluate average blood-sugar control.

Both the 9 mg and 12 mg retatrutide groups lowered A1C by an average of 2.2 percentage points from an average baseline A1C of 8.3%.

The Ozempic 2 mg group lowered A1C by 1.8 percentage points.

For people with type 2 diabetes, this difference matters because the retatrutide vs Ozempic comparison is not based on weight loss alone.

Blood-sugar control, cardiovascular health, kidney health, side effects, access, cost and a patient’s individual medical history can all influence treatment decisions.

3. Retatrutide Works Differently From Ozempic

Another important part of the retatrutide vs Ozempic story is how the drugs work.

Ozempic contains semaglutide and activates the GLP-1 receptor. The current U.S. prescribing information lists Ozempic as a once-weekly medicine for adults with type 2 diabetes, with additional cardiovascular and kidney-related indications for certain patients. Its maximum recommended dose for glycemic control is 2 mg once weekly.

Retatrutide is different.

It is an investigational triple hormone receptor agonist that activates:

GIP receptors
GLP-1 receptors
Glucagon receptors

Researchers are investigating whether targeting all three pathways together can produce stronger effects on blood sugar, appetite, energy balance and body weight.

The new Phase 3 findings strengthen interest in that approach, but regulatory approval will depend on review of the complete evidence package.

4. Side Effects and Treatment Discontinuation Still Matter

A larger average weight-loss number does not tell the entire story.

The most common adverse events reported with retatrutide were gastrointestinal problems such as diarrhea, nausea, constipation, vomiting and indigestion.

With retatrutide 12 mg, 32.7% experienced diarrhea and 23.8% experienced nausea. With Ozempic 2 mg, the corresponding rates were 26.4% and 21.3%.

Treatment discontinuation because of adverse events occurred in:

4.8% with retatrutide 9 mg
7.9% with retatrutide 12 mg
2.7% with Ozempic 2 mg

Most reported adverse events were described as mild to moderate.

These numbers matter when discussing retatrutide vs Ozempic because an effective treatment also has to be tolerable.

More average weight loss does not automatically make one medicine the best option for every patient.

5. Retatrutide Is Not FDA-Approved

This may be the most important point for readers who see retatrutide advertised online.

Retatrutide remains an investigational medicine.

Lilly states that it has not been approved by the FDA or any regulatory agency worldwide and is not legally marketed for routine patient use.

The company has also warned that unauthorized products advertised online as retatrutide may contain unknown ingredients, contaminants, incorrect amounts of an active ingredient or even a different ingredient altogether.

Readers should therefore avoid buying or injecting products advertised as retatrutide through social-media sellers, unofficial websites, research-chemical sellers or other unverified sources.

Lilly has said it plans to submit retatrutide for U.S. regulatory review for obesity in the first quarter of 2027. Submission does not guarantee approval.

6. This Was a Diabetes Trial, Not a General Obesity Trial

The retatrutide vs Ozempic numbers should not automatically be applied to every person trying to lose weight.

TRANSCEND-T2D-2 enrolled adults with type 2 diabetes whose blood sugar was inadequately controlled with metformin, with or without an SGLT2 inhibitor.

Participants had an average baseline BMI of approximately 36.8 kg/m².

The trial also compared retatrutide with Ozempic 2 mg, the maximum recommended weekly Ozempic dose for glycemic control.

Ozempic itself is approved for type 2 diabetes. Semaglutide is marketed separately as Wegovy for chronic weight management.

That distinction is important.

A head-to-head diabetes trial answers a specific clinical question. It should not automatically be treated as a comparison of every available obesity treatment.

7. Full Peer-Reviewed Results Are Still Needed

The October 28 announcement reported topline Phase 3 results.

Lilly says detailed TRANSCEND-T2D-2 findings will be presented at a future medical meeting and published in a peer-reviewed journal.

That means researchers, doctors and readers do not yet have every detail required for a complete independent assessment of the study.

The headline efficacy numbers also use an efficacy estimand designed to estimate outcomes if randomized participants had remained on their assigned study intervention for 80 weeks without prolonged use of additional glucose-lowering medication.

This is useful for estimating a drug’s effect under trial conditions, but it should not be interpreted as a guarantee that every person starting treatment in everyday practice would achieve the reported average weight loss.

Retatrutide vs Ozempic: Quick Comparison

In the current Phase 3 study, retatrutide was an investigational once-weekly triple agonist targeting GIP, GLP-1 and glucagon receptors.

Ozempic is an approved once-weekly semaglutide medicine that targets the GLP-1 receptor.

For retatrutide vs Ozempic, average weight loss after 80 weeks was:

19.5% — Retatrutide 9 mg
20.9% — Retatrutide 12 mg
9.4% — Ozempic 2 mg

Average A1C reductions were:

2.2 percentage points — Retatrutide 9 mg
2.2 percentage points — Retatrutide 12 mg
1.8 percentage points — Ozempic 2 mg

These findings strongly favor retatrutide on the measured efficacy outcomes in this particular study, but retatrutide also had higher treatment-discontinuation rates due to adverse events, especially at the 12 mg dose.

Does Retatrutide Cause More Weight Loss Than Ozempic?

For the retatrutide vs Ozempic question, this specific Phase 3 diabetes trial showed a clear difference: participants receiving the highest retatrutide dose lost an average of 20.9% of body weight, compared with 9.4% with Ozempic 2 mg at 80 weeks.

But these findings should not be generalized beyond the study.

Retatrutide remains unapproved, detailed peer-reviewed results are still pending, and healthcare decisions involve more than average weight loss alone.

What Should People Trying to Lose Weight Do Now?

For most people, the practical takeaway is not to chase an experimental medication.

Evidence-based weight management still includes sustainable nutrition, adequate protein, an appropriate calorie intake, regular physical activity, sufficient sleep and medical support when needed.

HealthFling readers can use the Protein Calculator and Calorie Calculator to estimate practical starting targets.

You can also read our Walking for Weight Loss guide for a simple way to increase daily movement.

If you currently use Ozempic or another prescription GLP-1 medicine, do not stop it, switch medicines or change the dose because of a headline about retatrutide.

Discuss medication decisions with the healthcare professional managing your treatment.

Eli Lilly — official TRANSCEND-T2D-2 results
Reuters — independent trial coverage
Lilly — what to know about retatrutide
Ozempic U.S. prescribing information

Frequently Asked Questions About Retatrutide vs Ozempic

Is retatrutide available now?

No. Retatrutide remains investigational and is not FDA-approved or legally marketed for routine patient use.

Is retatrutide the same as Ozempic?

No. Ozempic contains semaglutide and targets the GLP-1 receptor. Retatrutide is an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors.

How much weight did people lose with retatrutide?

In TRANSCEND-T2D-2, average weight loss at 80 weeks was 19.5% with retatrutide 9 mg and 20.9% with retatrutide 12 mg. The Ozempic 2 mg group lost 9.4% on average.

When could retatrutide be approved?

Lilly has said it plans to submit retatrutide for U.S. regulatory review for obesity in the first quarter of 2027. Filing an application does not guarantee FDA approval, and an exact launch date has not been established.

Should I switch from Ozempic to retatrutide?

No one should switch based solely on these topline results. Retatrutide is not an approved treatment, and changes to prescription medication should be discussed with a licensed healthcare professional.

The Bottom Line

The new retatrutide vs Ozempic Phase 3 results matter because they provide late-stage head-to-head evidence comparing retatrutide with an established incretin medicine.

In adults with type 2 diabetes, retatrutide produced greater average A1C reductions and substantially more weight loss than Ozempic 2 mg over 80 weeks.

The highest retatrutide dose was associated with 20.9% average weight loss versus 9.4% with Ozempic 2 mg.

At the same time, retatrutide remains investigational, side effects and treatment discontinuations matter, and complete peer-reviewed results are still pending.

The findings are promising, but they are not a reason to purchase unapproved products or change an existing prescription without medical guidance.

Medical Disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis or treatment. Prescription weight-loss and diabetes medications should only be used under the supervision of a qualified healthcare professional.